EICHOR
● Recruiting
Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)
Condition: Melanoma Metastatic · Sponsor: Centre Hospitalier Universitaire de Besancon
About this study
This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma. The complete histological response will be assessed.
This description comes directly from the study's public registry record.
Talk to the study team
Charlée NARDIN, MD PhD · cnardin@chu-besancon.fr
Always discuss trial participation with your own doctor first.
Locations (9)
| CHU Angers | Angers, France | Active Not Recruiting |
| CHU de Besançon | Besançon, France | Recruiting |
| Hôpital Avicenne | Bobigny, France | Active Not Recruiting |
| CH de Boulogne-sur-Mer | Boulogne-sur-Mer, France | Active Not Recruiting |
| CHU Clermont-Ferrand | Clermont-Ferrand, France | Active Not Recruiting |
| Centre de Lutte Contre le Cancer Léon Bérard | Lyon, France | Active Not Recruiting |
| ICO René Gauducheau | Saint-Herblain, France | Active Not Recruiting |
| Institut Universitaire de Cancérologie de Toulouse | Toulouse, France | Active Not Recruiting |
| CH de Valence | Valence, France | Active Not Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06586593